NCT06402136
Evaluation Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of 83-0060 in Healthy Volunteers
A Randomised, Double-Blind, Placebo-Controlled, First-in-Human Study of Orally Administered 83-0060 to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of 83-0060 in Healthy Volunteers
Traws Pharma, Inc.·Phase 1·ClinicalTrials.gov·drugRecruiting
View on ClinicalTrials.gov →Study focus
- Disease/Condition
- Healthy Volunteers Only
- Drug/Device/Intervention
- 83-0060
- Study type
- Interventional
- Intervention type
- drug
Sponsor & location
- Primary sponsor
- Traws Pharma, Inc.
- Location
- Sydney, Australia
Timeline & enrollment
- Phase
- Phase 1
- Start date
- Apr 15, 2024
- End date
- Sep 01, 2024
- Enrollment
- 64 participants
Primary outcome
Plasma concentration
Summary
This is a clinical study aiming to assess pharmacokinetics, pharmacodynamics and preliminary
 efficacy of 83-0060 in Healthy Volunteers
ICD-10 classifications
Healthy person accompanying sick personRoutine general health check-up of armed forcesRoutine general health check-up of sports teams
Data source
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT06402136
- Type
- Non-Device Trial
About this record
Access comprehensive clinical trial information for NCT06402136 through Pure Global AI's free database. This Phase 1 trial is sponsored by Traws Pharma, Inc. and is currently Recruiting. The study focuses on Healthy Volunteers Only. Target enrollment is 64 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.